학술논문

A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn’s disease. The Cross Pennine study II
Document Type
Article
Source
In: Alimentary Pharmacology and Therapeutics. (Alimentary Pharmacology and Therapeutics, April 2022, 55(7):856-866)
Subject
Language
English
ISSN
13652036
02692813